|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Trends in incidence and management of cancer of the ampulla of Vater显示文摘AIM:To provide trends in incidence,management and survival of cancer of the ampulla of Vater in a welldefined French population.METHODS:Data were obtained from the populationbased digestive cancer registry of Burgundy over a34-year period.Age-standardized incidence rates were computed using the world standard population.Average annual variations in incidence rates were estimated using a poisson regression.A univariate and multivariate relative survival analysis was performed.RESULTS:Age-standardized incidence rates were0.46 and 0.30 per 100000 inhabitants for men and women,respectively.Incidence rate increased from0.26(1976-1984)to 0.58(2003-2009)for men and remained stable for women.Resection for cure was performed in 48.3%of cases.This proportion was stable over the study period.Among cases with curative resection,pancreatico-duodenectomy was performed in94.0%of cases and ampullectomy in 6.0%of cases.A total of 50.8%of cancers of the ampulla of Vater were diagnosed at an advanced stage.Their proportion remained stable throughout the study period.The overall1-and 5-year relative survival rates were 60.2%and27.7%,respectively.Relative survival did not vary over time.Treatment and stage at diagnosis were the most important determinants of survival.The 5-year relative survival rate was 41.5%after resection for cure,9.5%after palliative surgery and 6.7%after symptomatic treatment.In multivariate analysis,only stage at diagnosis significantly influenced the risk of death.CONCLUSION:Cancer of the ampulla of Vater is still uncommon,but its incidence increased for men in Burgundy.Diagnosis is often made at an advanced stage,dramatically worsening the prognosis. | Florian Rostain Samia Hamza Antoine Drouillard Jean Faivre Anne-Marie Bouvier C?me Lepage | 2014 | World Journal of Gastroenterology2014，20，29： | 5 |
| 2 | Long-term risk of colorectal cancer after adenoma removal: a population-based cohort study显示文摘 | Vanessa Cottet Valérie Jooste Isabelle Fournel Anne-Marie Bouvier Jean Faivre Claire Bonithon-Kopp | 2012 | Gut2012，，8： | 4 |
| 3 | Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study显示文摘 | Laurent Beaugerie Nicole Brousse Anne Marie Bouvier Jean Frédéric Colombel Marc Lémann Jacques Cosnes Xavier Hébuterne Antoine Cortot Yoram Bouhnik Jean Pierre Gendre Tabassome Simon Marc Maynadié Olivier Hermine Jean Faivre Fabrice Carrat | 2009 | The Lancet . 2009 (9701)2009，，： | 4 |
| 4 | Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy显示文摘Advanced cholangiocarcinoma is associated with poor prognostic survival and has limited therapeutic options available at present. The importance of angiogenesis and expression of pro-angiogenic factors in intrahepatic forms of cholangiocarcinoma suggest that therapies targeting angiogenesis might be useful for the treatment of this disease. Here we report three cases of patients with advanced intrahepatic cholangiocarcinoma progressive after standard chemotherapy and treated with sunitinib 50 mg/d in 6-wk cycles of 4 wk on treatment followed by 2 wk off treatment(Schedule 4/2). In all three patients, sunitinib treatment was associated with a sustained disease control superior to 4 mo, patients achieving either a partial response or stable disease. A reduction in tumor size and density was observed in all cases, suggesting tumor necrosis as a result of sunitinib treatment in these patients. In addition, sunitinib was generally well tolerated and the occurrence of side effects was managed with standard medical interventions, as required. Our results suggest that sunitinib therapy maybe associated with favorable outcomes and tolerability in patients with advanced cholangiocarcinoma. Those observations contributed to launch a prospective phase Ⅱ multicenter trial investigating sunitinib in advanced intrahepatic cholangiocarcinoma(SUN-CK study; NCT01718327). | Chantal Dreyer Marie-Paule Sablin Mohamed Bouattour Cindy Neuzillet Maxime Ronot Safi Dokmak Jacques Belghiti Nathalie Guedj Valérie Paradis Eric Raymond Sandrine Faivre | 2015 | World Journal of Hepatology2015，7，6： | 4 |
| 5 | Stromal expression of SPARC in pancreatic adenocarcinoma显示文摘 | Cindy Neuzillet Annemila? Tijeras-Raballand Jér?me Cros Sandrine Faivre Pascal Hammel Eric Raymond | 2013 | Cancer and Metastasis Reviews (-)2013，，3： | 4 |
| 6 | Epidemiology and Management of Liver Metastases From Colorectal Cancer显示文摘 | Sylvain Manfredi C?me Lepage Cyril Hatem Olivier Coatmeur Jean Faivre Anne-Marie Bouvier | 2006 | Annals of Surgery2006，，2： | 2 |
| 7 | Therapeutic efficiency of everolimus and lapatinib in xenograft model of human colorectal carcinoma with KRAS mutation显示文摘 | Céline Chu Marie‐Sophie No?l‐Hudson Valérie Boige Diane Goéré Sylvie Marion Mélanie Polrot Ludovic Bigot Patrick Gonin Robert Farinotti Laurence Bonhomme‐Faivre | 2013 | Fundamental & Clinical Pharmacology2013，，4： | 2 |
| 8 | Safety of Liver Resection for Hepatocellular Carcinoma After Sorafenib Therapy: A Multicenter Case-Matched Study显示文摘 | Louise Barbier David Fuks Patrick Pessaux Fabrice Muscari Yves-Patrice Treut Sandrine Faivre Jacques Belghiti | 2013 | Annals of Surgical Oncology2013，，11： | 2 |
| 9 | Cellular and molecular pharmacology of oxaliplatin显示文摘 | Faivre S Chaney S | 2002 | Mol Cancer Ther2002，1，3： | 1 |
| 10 | Activation of cellular invasion by trefoil peptides and src is mediated by cyclooxygenase-2 and thromboxane A2 receptor-dependent signaling pathways显示文摘 | Rodrigues S Nguyen QD Faivre S | 2001 | FASEB J2001，15，9： | 1 |
| 11 | Oxaliplatin : mechanism of action and antinoplastin显示文摘 | Raymond E Faivre S Woynarowski JM | 1998 | Semin Oncol1998，25，5： | 1 |
| 12 | Accelerated in vitro differentiation of blood monocytes into dendritic cells in human sepsis 显示文摘 | Faivre V Lukaszewicz AC Alves A | 2007 | Clin Exp Immuno12007，147，3： | 1 |
| 13 | Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharidetreated rabbits:comparison with dobutamine and milrinone显示文摘 | Barraud D Faivre V Damy T | | 0，，05： | 1 |
| 14 | Validation of 213Bi-alpha radioimmunotherapy for multiple myeloma显示文摘 | Couturier O Faivre Chauvet A Filippovich IV | 1999 | Clin Cancer Res1999，5，10： | 1 |
| 15 | Oxaliplatin: mechanism of action and antinoplastin activity 显示文摘 | Raymond E Faivre S Woynarowski JM | 1998 | Semin Oncol1998，25，5： | 1 |
| 16 | Activation of cellular invasion by trefoil peptides and src is mediated by cyclooxygenaseand thromboxane A2 receptor-dependent signaling pathways显示文摘 | Rodrigues S Nguyen Q D Faivre S | 2001 | J Faseb2001，15，9： | 1 |
| 17 | Safety,pharmacokinetic,and antitumor activity of SU11248,a novel oral multitarget tyrosine kinase inhibitor,in patients with cancer显示文摘 | Faivre S Delbaldo C Vera K | 2006 | J Clin Oncol2006，24，1： | 1 |
| 18 | A simple HPL C-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma 显示文摘 | FAIVRE L GOMO C MIR O | 2011 | J Chromatogr B Analyt Technol Biomed Life Sci2011，879，23： | 1 |
| 19 | Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma显示文摘 | Supiot S Faivre Chauvet A Couturier O | 2002 | Cancer2002，94，4： | 1 |
| 20 | Safety, pharmacokinetic, and antitumor activity of SUl1248, a novel oral multitarget tyrosine kinase inhibitor,in patients with cancer显示文摘 | FAIVRE S DELBALDO C VERA K | 2006 | J ClinOnco12006，24，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员